Breast Cancer Prevention (cont.)

Medical Author:
Medical Editor:
Medical Editor:

How helpful are BRCA1 and BRCA2 genetic tests in identifying women at risk?

In special circumstances, genetic tests can be very helpful both in identifying exceptionally high-risk patients and reducing the level of concern for others. We also now know that the presence of one of these genetic defects does not cause cancer in every patient.

Before genetic tests are conducted, individuals being tested must have thorough counseling. A clear understanding of the limitations of the tests and the problems they may pose must precede the testing. The patient must know the meaning of the possible results, whichever way they may turn out, before testing. They should also have settled on a plan for each possible outcome of the test results. Often, the best way to evaluate a potential genetic risk is to test a relative who has already been diagnosed with breast cancer. If the relative's genetic testing (which must cover a large number of possible mutations) proves negative, then there is no need to perform genetic testing on the concerned individual. But the concerned individual should still undergo close monitoring with breast examinations and mammograms. If the test is positive on the relative, then that specific mutation is the only one that needs to be checked in the concerned individual and the other family members.

What is the link between estrogen and breast cancer?

Estrogen is a female hormone that is produced by the ovaries. During the reproductive years, a woman's body is exposed to high levels of estrogen. After menopause, the production of estrogen by the ovaries decreases. Estrogen is sometimes prescribed to treat some of the problems often associated with menopause, such as hot flashes, night sweats, sleeplessness, and vaginal dryness. Estrogen has the additional benefit of prevention of bone thinning (osteoporosis). However, results from a large clinical trial of postmenopausal women receiving hormone therapy (HT) released in 2002 showed that the overall risks of estrogen plus progestin therapy outweighed the benefits of hormone therapy. Combined hormone therapy with estrogen and progestin was shown to increase the risk of heart disease, stroke, and blood clots.

High levels of estrogen over long periods also increase the risk of developing breast and uterine cancer. Estrogen stimulates the cells of the breast and the uterine lining to grow and divide. Breast cells that are actively dividing are believed to have a greater chance of DNA damage as well as a higher number of cells that already have DNA damage. A higher number of cells with DNA damage elevate the risk of cancer development.

Women who have an early onset of their menstrual period (or menses) and late menopause are more likely to develop breast cancer than women with late menses onset and early menopause. This difference is believed to be attributable to the longer period of estrogen exposure in the first group.

Medically Reviewed by a Doctor on 10/10/2014

Patient Comments

Viewers share their comments

Breast Cancer Prevention - Mammograms Question: How often do you get a mammogram? How old were you when you received your first screening?
Breast Cancer Prevention - Genetic Tests Question: Does your family have a history of breast or other cancers? Have any relatives been tested for the BRCA1 and BRCA2 genes?
Breast Cancer Prevention - Early Detection Question: Were you diagnosed with early stage breast cancer? If so, what was the treatment?
Breast Cancer Prevention - Foods Question: Are you eating certain foods to reduce your risk of breast cancer?